$80MSeries A, 6 January 2026
Dosed first patients in a Phase 1 trial of PCSK9 siRNA COR-1004; funds also advance COR-2003.
- Amount
- $80M
- Stage
- Series A
- Announced
- 6 January 2026
- Lead
- Forbion
- Other investors
- Population Health Partners, John Maraganore
- Use of funds
- Dosed first patients in a Phase 1 trial of PCSK9 siRNA COR-1004; funds also advance COR-2003.
- Checked
- Announced by the company
- Sources
- Corsera Health announces $80M Series A financing businesswire.com
Corsera Health announces $80M Series A financing pulse2.com